Cancer-derived Exos can activate transforming signaling pathways in recipients cells by transferring oncogenic proteins such as mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) proteins [51] or the epidermal growth factor receptor variant III [52]. Here, KRAS is linked to cancer.